Skip to main content Accessibility help
  • Print publication year: 2013
  • Online publication date: August 2013

15 - Whatis the risk of cancer with hormonal contraception?


The contraceptive consultation differs across international healthcare systems in relation to the setting, scope of practice, provider-responsibility and the available time frame. The key to a successful consultation is to ensure that the patient leaves with their contraceptive needs met, either with the immediate provision of a contraceptive method or a plan for initiation at a specified future date. This chapter provides guidance on how to fulfill this outcome. In a generalist setting, posters inviting patients to discuss sexual health issues, brochures on contraception and information on confidentiality may be of assistance in setting the scene for the consultation. Where time is limited, an effective contraception consultation lies in its shaping. There are a variety of tools ranging from websites to models that can be useful to support a contraceptive consultation. The chapter presents cases, which illustrate approaches and principles in a sample of contraceptive consultations across the reproductive lifespan.


1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative re-analysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713–27.
2. Kahlenborn C, Modugno F, Potter DM, Severs WB. Oral contraception use as a risk factor for premenopausal breast cancer: a meta-analysis. Mayo Clin Proc 2006; 81: 1290–302.
3. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical cancer and hormonal contraceptives: collaborative re-analysis of individual data for 16 753 women with cervical cancer and 35 509 women without cervical cancer from 24 epidemiological studies. Lancet 2007; 370: 1609–21.
4. Maheshwari S, Sarraj A, Kramer J, El-Serag HB. Oral contraception and the risk of hepatocellular carcinoma. J Hepatol 2007; 47: 506–13.
5. La Vecchia C, Ron E, Francheschi S, et al. A pooled analysis of case-control studies of thryoid cancer. III. Oral contraceptives, menopausal replacement therapy and other female hormones. Cancer Causes Control 1999; 10: 157–66.
6. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative re-analysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls. Lancet 2008; 371: 303–14.
7. Schlesselman JJ. Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner's guide to meta-analysis. Hum Reprod 1997; 12: 1851–63.
8. Bosetti C, Bravi F, Negri E, La Vecchia C. Oral contraceptives and colorectal cancer risk: a systematic review and meta-analysis. Human Reprod Update 2009; 15: 489–98.
9. IARC Working Group. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 91. Combined Estrogen–Progestogen Contraceptives and Combined Estrogen–Progestogen Menopausal Therapy. Lyon, France: International Agency for Research on Cancer, 2007.
10. Hannaford PC, Iversen L, MacFarlane TV, et al. Mortality among oral contraceptive users: cohort evidence from the Royal College of General Practitioners' Oral Contraception Study. BMJ 2010; 340: c927.